Mechlorethamine HCl and cyclophosphamide in the treatment of Hodgkin's disease and the lymphomas

Publisher Website
Google Scholar
Abstract
Eight-six patients (37 with Hodg-kin''s, 37 with lymphosarcoma, and 12 with reticulum cell sarcoma) were randomized and treated with either a single dose of mechlorethamine HC1 (0.4 mg/kg of body weight, given intravenously) followed by daily maintenance with chlorambucil (given orally), or a loading dose of cyclophosphamide (40 mg/kg of body weight, given intraven ously) followed by daily maintenance with cyclophosphamide (given orally). No significant difference was observed between these 2 regimens in frequency of objective tumor response 45% of patients who received mechlorethamine and 57% who received cyclophosphamide had an objective response. Marked alopecia was the only significant difference in toxic effects, occurring in 36% of the patients receiving cyclophosphamide and in 1 patient receiving mechlorethamine. A slight platelet-sparing effect of cyclophosphamide over mechlorethamine and chlorambucil was not considered clinically significant.

This publication has 2 references indexed in Scilit: